Samsung Debuts New Ultrasound Modality Geared Toward Women's Health and Urology
Combining enhanced imaging capabilities, workflow efficiencies and artificial intelligence (AI)-enabled technology to improve the diagnosis and management of health conditions in women, Samsung has launched the V6 ultrasound system.
Advances in artificial intelligence (AI) technology and image sharing tools with Samsung’s new V6 ultrasound platform may facilitate enhanced workflow efficiencies in the management of women’s health conditions.
Samsung noted that key advances with the V6 ultrasound system include:
• one-click fetal growth measurements with the semi-automated BiometryAssist™ feature;
• AI-enabled uterus measurements to help detect uterine-related abnormalities with UterineAssist™; and
• real-time image sharing between sonographers and referring physicians with the SonoSync™ feature.
The V6 ultrasound platform also features a miniER7 endocavity transducer, which gives clinicians a 180-degree field of view, a frequency range between 2 and 12 MHz, and design enhancements that may enhance patient comfort, according to Samsung.
“The V6 was developed with the clinical needs of women’s health and urology specifically in mind,” said Tracy Bury, a women’s health segment leader for Boston Imaging, the United States headquarters of Samsung’s digital radiography and ultrasound business. “We’re proud to offer a new product that is not only accessible to a broad group of clinicians but also has innovative, automated features that can make patient care simpler and more efficient.”
Large Study Affirms Safety of Ultrasound Enhancing Agents for Echocardiography
May 16th 2025Those receiving ultrasound enhancing agents (UEAs) for transthoracic or stress echocardiography had lower odds of all-cause death in comparison to patients who did not have UEAs, according to a nationwide study involving 11.4 million patients.
Can Emerging AI Software Offer Detection of CAD on CCTA on Par with Radiologists?
May 14th 2025In a study involving over 1,000 patients who had coronary computed tomography angiography (CCTA) exams, AI software demonstrated a 90 percent AUC for assessments of cases > CAD-RADS 3 and 4A and had a 98 percent NPV for obstructive coronary artery disease.
